Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (GB:0QCV)
LSE:0QCV
Holding GB:0QCV?
Track your performance easily
0QCV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$136.34 - $208.50
Previous Close$200.86
Volume2.01K
Average Volume (3M)17.90K
Market Cap
$352.54B
Enterprise Value$416.38B
Total Cash (Recent Filing)$7.29B
Total Debt (Recent Filing)$71.08B
Price to Earnings (P/E)70.0
Beta0.30
Next Earnings
Jan 29, 2025EPS Estimate
$2.97Next Dividend Ex-Date
Jan 15, 2025Dividend Yield3.11%
Share Statistics
EPS (TTM)2.87
Shares Outstanding1,767,140,323
10 Day Avg. Volume211
30 Day Avg. Volume17,904
Standard Deviation0.10
R-Squared0.00552
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)23.40
Price to Sales (P/S)6.38
Price to Cash Flow (P/CF)16.30
P/FCF Ratio15.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.50
Enterprise Value/Gross Profit12.28
Enterprise Value/Ebitda22.88
Forecast
1Y Price Target
$213.71Price Target Upside6.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
AbbVie News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbbVie reported solid 3Q results driven by Skyrizi/Rinvoq and oncology portfolio beats, and raised 2024 revenue guidance to $56B.
Growth PotentialEmraclidine is highlighted as a potential catalyst for further upside to shares with registrational data expected later this year.
Strategic ExpansionAbbVie announced a definitive agreement to acquire privately-held biotech company Aliada for $1.4B in cash.
Bears Say
Earnings GuidanceThe company lowered 2024 aesthetics guidance to $5.5bn from $5.7bn.
Market PerformanceJuvederm is particularly challenged by macro weakness due to its higher price point.
Product SalesDownside risk from lower Humira sales and loss of exclusivity in the US.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
22.02% Mutual Funds
5.11% Other Institutional Investors
51.71% Public Companies and
Individual Investors
0QCV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest share price was $136.34 and its highest was $208.50 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 29, 2025 which is in 80 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Oct 30, 2024. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.08.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 3.11%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is $2.97.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $3 in its last earnings report, beating expectations of $2.92. Following the earnings report the stock price went up 5.907%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 233M.
---
AbbVie Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$213.71 (6.40% Upside)
$213.71 (6.40% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 94%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.59%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
0QCV Earnings Call
Q3 2024
0:00 / 0:00
---
0QCV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
0QCV Stock 12 Month Forecast
Average Price Target
$213.71
▲(6.40% Upside)
Technical Analysis
Best Analysts Covering 0QCV
1 Year
1 Year Success Rate
15/15 ratings generated profit
1 Year Average Return
+22.67%
reiterated a buy rating 11 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +22.67% per trade.
---